Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Florida: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 249 | 31,886 | 49% |
| 2020 | 263 | 33,442 | 52% |
| 2021 |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 13% of the cases CMS names in Florida; 183 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 452 | 65,364+17%/yr | +17%/yr | 29.8 | 92% | 129,200 in 2030+12%/yr |
| North Carolina | 229 |
CGM & insulin pump management in every state, and its device makers · Every procedure market in Florida · Every state · Compare with Texas
| 2025 est. |
| ≈ 80,600 |
| – |
| 2026 est. | ≈ 89,000 | – |
| 308 |
| 42,928 |
| 54% |
| 2022 | 334 | 49,543 | 56% |
| 2023 | 360 | 56,948 | 58% |
| 2024 | 404 | 65,371 | 60% |
| 2025 from claims | – | 80,633 73,999–85,310 | 61% |
| 2026 forecast | – | 89,029 78,331–102,735 | 61% |
| 2027 forecast | – | 97,911 83,703–116,680 | 61% |
| 2028 forecast | – | 107,666 89,837–131,834 | 62% |
| 2029 forecast | – | 118,379 96,688–148,458 | 62% |
| 2030 forecast | – | 130,142 104,262–166,775 | 63% |
In 2025, 4% hospital outpatient, 96% office. The share outside the hospital has moved −4 pts since 2019.
| 28,955+18%/yr |
| +18%/yr |
| 28.6 |
| 87% |
| 48,600 in 2030+9%/yr |
| Georgia | 210 | 27,583+22%/yr | +22%/yr | 31.3 | 99% | 50,800 in 2030+11%/yr |
| Maryland | 171 | 26,549+30%/yr | +30%/yr | 29.8 | 87% | 49,300 in 2030+11%/yr |
| Virginia | 186 | 25,175+32%/yr | +32%/yr | 23.7 | 75% | 49,200 in 2030+12%/yr |
| Tennessee | 150 | 20,740+27%/yr | +27%/yr | 29.0 | 93% | 38,400 in 2030+11%/yr |
| South Carolina | 108 | 17,936+27%/yr | +27%/yr | 25.8 | 93% | 35,200 in 2030+12%/yr |
| Kentucky | 110 | 12,522+26%/yr | +26%/yr | 26.8 | 83% | 22,100 in 2030+9.9%/yr |
| Oklahoma | 89 | 11,902+33%/yr | +33%/yr | 24.2 | 84% | 19,400 in 2030+8.5%/yr |
| Alabama | 73 | 11,837+23%/yr | +23%/yr | 26.4 | 81% | 19,400 in 2030+8.6%/yr |
| Mississippi | 54 | 11,559+40%/yr | +40%/yr | 30.4 | 85% | 20,500 in 2030+10%/yr |
| Louisiana | 83 | 11,500+25%/yr | +25%/yr | 27.6 | 78% | 18,600 in 2030+8.3%/yr |
| Arkansas | 47 | 10,160+31%/yr | +31%/yr | 26.5 | 84% | 16,600 in 2030+8.6%/yr |
| Delaware | 25 | 4,890+35%/yr | +35%/yr | 28.2 | 80% | 8,660 in 2030+10%/yr |
| West Virginia | 43 | 4,488+28%/yr | +28%/yr | 21.1 | 34% | 8,070 in 2030+10%/yr |
| District of Columbia | 17 | 1,276+12%/yr | +12%/yr | 20.1 | 100% | 2,370 in 2030+11%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Insulet leads with 32% of company spending on these surgeons in 2025, +13 pts on 2024.
In 2025, 12 companies reported engagement with Florida’s surgeons worth $1.1M in consulting, speaking, meals and travel tied to these products, about $2,711 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.